FR2918276B1 - "utilisation d'un gel de polysaccharide(s)naturel(s)pour la preparation d'une formulation injectable de traitement des degenerescences articulaires" - Google Patents

"utilisation d'un gel de polysaccharide(s)naturel(s)pour la preparation d'une formulation injectable de traitement des degenerescences articulaires"

Info

Publication number
FR2918276B1
FR2918276B1 FR0704772A FR0704772A FR2918276B1 FR 2918276 B1 FR2918276 B1 FR 2918276B1 FR 0704772 A FR0704772 A FR 0704772A FR 0704772 A FR0704772 A FR 0704772A FR 2918276 B1 FR2918276 B1 FR 2918276B1
Authority
FR
France
Prior art keywords
degenerescences
gel
joint
preparation
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0704772A
Other languages
English (en)
Other versions
FR2918276A1 (fr
Inventor
Molliard Samuel Gavard
Olivier Benoit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
APTISSEN SA, CH
Original Assignee
Anteis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39167393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2918276(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anteis SA filed Critical Anteis SA
Priority to FR0704772A priority Critical patent/FR2918276B1/fr
Priority to EP08827889.0A priority patent/EP2173324B1/fr
Priority to PL19156054T priority patent/PL3498262T3/pl
Priority to PL08827889T priority patent/PL2173324T3/pl
Priority to ES19156054T priority patent/ES2898939T3/es
Priority to CA2691600A priority patent/CA2691600C/fr
Priority to BRPI0813011A priority patent/BRPI0813011B8/pt
Priority to PCT/FR2008/000948 priority patent/WO2009024670A2/fr
Priority to US12/667,627 priority patent/US9138405B2/en
Priority to JP2010514043A priority patent/JP5517133B2/ja
Priority to EP19156054.9A priority patent/EP3498262B1/fr
Priority to TR2019/09779T priority patent/TR201909779T4/tr
Priority to HUE19156054A priority patent/HUE056793T2/hu
Priority to KR20097027301A priority patent/KR20100028582A/ko
Priority to CN201510090635.XA priority patent/CN104825482A/zh
Priority to PT08827889T priority patent/PT2173324T/pt
Priority to ES08827889T priority patent/ES2735376T3/es
Priority to PT191560549T priority patent/PT3498262T/pt
Priority to CN200880023126A priority patent/CN101686936A/zh
Publication of FR2918276A1 publication Critical patent/FR2918276A1/fr
Publication of FR2918276B1 publication Critical patent/FR2918276B1/fr
Application granted granted Critical
Priority to US14/827,681 priority patent/US10028976B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0023—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0052—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/008—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
FR0704772A 2007-07-02 2007-07-02 "utilisation d'un gel de polysaccharide(s)naturel(s)pour la preparation d'une formulation injectable de traitement des degenerescences articulaires" Active FR2918276B1 (fr)

Priority Applications (20)

Application Number Priority Date Filing Date Title
FR0704772A FR2918276B1 (fr) 2007-07-02 2007-07-02 "utilisation d'un gel de polysaccharide(s)naturel(s)pour la preparation d'une formulation injectable de traitement des degenerescences articulaires"
EP19156054.9A EP3498262B1 (fr) 2007-07-02 2008-07-02 Gel injectable d'acide hyaluronique
HUE19156054A HUE056793T2 (hu) 2007-07-02 2008-07-02 Injektálható hialuronsav-gél
PL08827889T PL2173324T3 (pl) 2007-07-02 2008-07-02 Zastosowanie żelu z polisacharydu(ów) naturalnego(ych) do wytwarzania kompozycji do wstrzykiwania w celu leczenia zwyrodnień stawów
ES19156054T ES2898939T3 (es) 2007-07-02 2008-07-02 Gel inyectable de ácido hialurónico
CA2691600A CA2691600C (fr) 2007-07-02 2008-07-02 Utilisation d'un gel de polysaccharide(s) naturel(s) pour la preparation d'une formulation injectable de traitement des degenerescences articulaires
BRPI0813011A BRPI0813011B8 (pt) 2007-07-02 2008-07-02 formulação injetável aquosa estéril, processo de preparação da mesma e sua utilização
PCT/FR2008/000948 WO2009024670A2 (fr) 2007-07-02 2008-07-02 Gel injectable d ' acide hyaluronique pour le traitement des degenerescences articulaires
US12/667,627 US9138405B2 (en) 2007-07-02 2008-07-02 Use of a natural polysaccharide gel for the preparation of an injectable formulation for treatment of articular degeneration
JP2010514043A JP5517133B2 (ja) 2007-07-02 2008-07-02 関節変性の治療のための注射用製剤の製造のための天然ポリサッカライドゲルの使用
EP08827889.0A EP2173324B1 (fr) 2007-07-02 2008-07-02 Gel injectable d'acide hyaluronique pour le traitement des degenerescences articulaires
TR2019/09779T TR201909779T4 (tr) 2007-07-02 2008-07-02 Eklem dejenerasyonu tedavisine yönelik enjekte edilebilir hyalüronik asit jeli.
PL19156054T PL3498262T3 (pl) 2007-07-02 2008-07-02 Kwas hialuronowy - żel do wstrzykiwania
KR20097027301A KR20100028582A (ko) 2007-07-02 2008-07-02 관절 퇴행의 치료를 위한 히알루론산 주사 겔
CN201510090635.XA CN104825482A (zh) 2007-07-02 2008-07-02 天然多糖凝胶剂在制备用于治疗关节退行性变的可注射制剂中的应用
PT08827889T PT2173324T (pt) 2007-07-02 2008-07-02 Gel injetável de ácido hialurónico para tratamento de degenerescências articulares
ES08827889T ES2735376T3 (es) 2007-07-02 2008-07-02 Gel inyectable de ácido hialurónico para el tratamiento de la degeneración articular
PT191560549T PT3498262T (pt) 2007-07-02 2008-07-02 Gel injetável de ácido hialurónico
CN200880023126A CN101686936A (zh) 2007-07-02 2008-07-02 天然多糖凝胶剂在制备用于治疗关节退行性变的可注射制剂中的应用
US14/827,681 US10028976B2 (en) 2007-07-02 2015-08-17 Injectable formulation of natural polysaccharide and polyol for treatment of osteoarthritis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0704772A FR2918276B1 (fr) 2007-07-02 2007-07-02 "utilisation d'un gel de polysaccharide(s)naturel(s)pour la preparation d'une formulation injectable de traitement des degenerescences articulaires"

Publications (2)

Publication Number Publication Date
FR2918276A1 FR2918276A1 (fr) 2009-01-09
FR2918276B1 true FR2918276B1 (fr) 2010-01-22

Family

ID=39167393

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0704772A Active FR2918276B1 (fr) 2007-07-02 2007-07-02 "utilisation d'un gel de polysaccharide(s)naturel(s)pour la preparation d'une formulation injectable de traitement des degenerescences articulaires"

Country Status (14)

Country Link
US (1) US9138405B2 (fr)
EP (2) EP2173324B1 (fr)
JP (1) JP5517133B2 (fr)
KR (1) KR20100028582A (fr)
CN (2) CN101686936A (fr)
BR (1) BRPI0813011B8 (fr)
CA (1) CA2691600C (fr)
ES (2) ES2898939T3 (fr)
FR (1) FR2918276B1 (fr)
HU (1) HUE056793T2 (fr)
PL (2) PL3498262T3 (fr)
PT (2) PT3498262T (fr)
TR (1) TR201909779T4 (fr)
WO (1) WO2009024670A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11654428B2 (en) 2019-01-21 2023-05-23 Vias Partners, Llc Methods, systems and apparatus for separating components of a biological sample

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2945949B1 (fr) 2009-05-26 2011-05-13 Anteis Sa Hydrogel injectable permettant une supplementation en glycerol dans la peau sur le long terme.
US8273725B2 (en) 2009-09-10 2012-09-25 Genzyme Corporation Stable hyaluronan/steroid formulation
FR2954165B1 (fr) 2009-12-18 2012-01-13 Jean-Noel Thorel Compositions injectables a usage intra-articulaire associant un agent de viscosupplementation et un milieu de croissance des fibroblastes
JP5457238B2 (ja) * 2010-03-17 2014-04-02 電気化学工業株式会社 ヒアルロン酸及び／又はその塩の含有液の加熱滅菌方法
IT1402382B1 (it) * 2010-09-09 2013-09-04 Ibsa Inst Biochimique Sa Complessi cooperativi ibridi di acido ialuronico
US8455436B2 (en) 2010-12-28 2013-06-04 Depuy Mitek, Llc Compositions and methods for treating joints
US8524662B2 (en) 2010-12-28 2013-09-03 Depuy Mitek, Llc Compositions and methods for treating joints
US8398611B2 (en) 2010-12-28 2013-03-19 Depuy Mitek, Inc. Compositions and methods for treating joints
US20140038917A1 (en) * 2011-04-19 2014-02-06 Anteis S.A. Sterile and injectable aqueous formulation for administration in the intra-articular space of an intra-articular joint
US8623839B2 (en) * 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
GB201118586D0 (en) * 2011-10-27 2011-12-07 Turzi Antoine New A-PRP medical device, manufacturing machine and process
WO2013076160A1 (fr) * 2011-11-21 2013-05-30 Université Libre de Bruxelles Formulations à libération prolongée utiles dans le traitement de maladies
WO2013076162A1 (fr) * 2011-11-21 2013-05-30 Université Libre de Bruxelles Formulations utiles dans le traitement de maladies ostéoarticulaires
FR2991876B1 (fr) 2012-06-13 2014-11-21 Vivacy Lab Composition, en milieu aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate
FR2994846B1 (fr) 2012-08-29 2014-12-26 Vivacy Lab Composition, sterilisee, comprenant au moins un acide hyaluronique et de l'ascorbyl phosphate de magnesium
WO2014110454A1 (fr) * 2013-01-11 2014-07-17 Carbylan Biosurgery, Inc. Compositions stabilisées comprenant de l'acide hyaluronique
PT3019177T (pt) 2013-07-10 2020-12-30 Matrix Biology Inst Composições de hialuronano de elevada elasticidade e suas utilizações
KR101582380B1 (ko) * 2013-09-11 2016-01-05 주식회사 제네웰 손상 조직에 대한 세포 전달 및 조직 재생용 생체재료와 제조방법
WO2015077736A1 (fr) 2013-11-25 2015-05-28 Deuteria Biomaterials, Llc Hyaluronane enrichi en deutérium
US9682099B2 (en) 2015-01-20 2017-06-20 DePuy Synthes Products, Inc. Compositions and methods for treating joints
FR3032617B1 (fr) * 2015-02-16 2018-03-16 Kylane Laboratoires Sa Procede de preparation d un hydrogel injectable; hydrogel obtenu; utilisation de l hydrogel obtenu
PL3352766T3 (pl) 2015-09-24 2021-08-02 Matrix Biology Institute Kompozycie z hialuronanem o dużej elastyczności i sposoby ich użycia
CN105879124B (zh) * 2016-04-26 2019-03-19 华熙福瑞达生物医药有限公司 一种注射用左旋聚乳酸填充剂及其制备方法
KR101916193B1 (ko) 2016-08-25 2018-11-07 주식회사 파마리서치프로덕트 핵산 및 키토산을 포함하는 관절강 주사용 조성물
US10576099B2 (en) 2016-10-21 2020-03-03 Covidien Lp Injectable scaffold for treatment of intracranial aneurysms and related technology
FR3063649B1 (fr) * 2017-03-07 2021-05-21 Laboratoire De Rhumatologie Appliquee Nouvelle solution visco-elastique et son utilisation en rhumatologie
WO2019038763A1 (fr) 2017-08-22 2019-02-28 Moebius Medical Ltd. Formulation liposomale pour lubrification d'articulation
IT201800007683A1 (it) 2018-07-31 2020-01-31 Altergon Sa Composizioni cooperative sinergiche utili per aumento del tessuto molle, rilascio di farmaco e campi correlati
WO2020111888A1 (fr) * 2018-11-30 2020-06-04 주식회사 엘지화학 Composition de supplément de liquide synovial comprenant de l'acide hyaluronique
EP3854377A1 (fr) * 2020-01-22 2021-07-28 Laboratoires Genevrier Sas Composition comprenant de l'acide hyaluronique et un polyol ou de carboxyméthylcellulose

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL80298A (en) 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
US5079236A (en) 1987-05-27 1992-01-07 Hyal Pharmaceutical Corporation Pure, sterile, pyrogen-free hyaluronic acid formulations their methods of preparation and methods of use
AU621305B2 (en) * 1987-07-01 1992-03-12 Genentech Inc. Method and therapeutic compositions for the prevention of fibrin deposition or adhesions
JP2788340B2 (ja) * 1989-12-21 1998-08-20 株式会社ニッショー 炎症治療剤
US5095037B1 (en) * 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
CA2060223C (fr) * 1991-02-12 1999-07-20 Clarence C. Lee Composition de fluide lubrifiant medical injectable et methode d'utilisation
US7968110B2 (en) * 1992-02-11 2011-06-28 Merz Aesthetics, Inc. Tissue augmentation material and method
IT1291291B1 (it) * 1997-04-30 1999-01-07 Chemedica Sa Uso di acido ialuronico e relativi sali per la preparazione di una soluzione acquosa utile come liquido di lavaggio intra-articolare
US20030203030A1 (en) * 2002-01-18 2003-10-30 Control Delivery Systems, Inc. Polymeric gel delivery system for pharmaceuticals
WO2004073759A1 (fr) 2003-02-19 2004-09-02 Aventis Pharmaceuticals Holdings Inc. Composition et methode pour augmenter le tissu mou intradermique
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
FR2865737B1 (fr) * 2004-02-03 2006-03-31 Anteis Sa Gel reticule biocompatible
US20050215516A1 (en) 2004-03-29 2005-09-29 Claudio Bucolo New free-radical scavenger containing viscoelastic composition, methods of use and package
AU2005272578A1 (en) * 2004-08-13 2006-02-23 Angiotech International Ag Compositions and methods using hyaluronic acid and hyluronidase inhibitors
WO2006067608A1 (fr) * 2004-12-22 2006-06-29 Laboratoire Medidom S.A. Formulations aqueuses a base de hyaluronate de sodium a usage parenteral
FR2895907B1 (fr) * 2006-01-06 2012-06-01 Anteis Sa Gel viscoelastique a usage dermatologique
FR2909560B1 (fr) 2006-12-06 2012-12-28 Fabre Pierre Dermo Cosmetique Gel d'acide hyaluronique pour injection intradermique

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11654428B2 (en) 2019-01-21 2023-05-23 Vias Partners, Llc Methods, systems and apparatus for separating components of a biological sample

Also Published As

Publication number Publication date
EP2173324B1 (fr) 2019-04-10
ES2898939T3 (es) 2022-03-09
BRPI0813011A2 (pt) 2014-12-23
CA2691600C (fr) 2017-01-10
EP2173324A2 (fr) 2010-04-14
WO2009024670A3 (fr) 2009-04-23
HUE056793T2 (hu) 2022-03-28
PL2173324T3 (pl) 2019-09-30
US20100184720A1 (en) 2010-07-22
CN101686936A (zh) 2010-03-31
JP5517133B2 (ja) 2014-06-11
FR2918276A1 (fr) 2009-01-09
BRPI0813011B8 (pt) 2021-05-25
TR201909779T4 (tr) 2019-07-22
ES2735376T3 (es) 2019-12-18
PT2173324T (pt) 2019-07-09
CN104825482A (zh) 2015-08-12
JP2010531863A (ja) 2010-09-30
US9138405B2 (en) 2015-09-22
CA2691600A1 (fr) 2009-02-26
PL3498262T3 (pl) 2022-02-07
EP3498262A1 (fr) 2019-06-19
EP3498262B1 (fr) 2021-09-01
KR20100028582A (ko) 2010-03-12
WO2009024670A2 (fr) 2009-02-26
BRPI0813011B1 (pt) 2019-10-08
PT3498262T (pt) 2021-11-11

Similar Documents

Publication Publication Date Title
FR2918276B1 (fr) "utilisation d'un gel de polysaccharide(s)naturel(s)pour la preparation d'une formulation injectable de traitement des degenerescences articulaires"
FR2935611B1 (fr) Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
FR2921260B1 (fr) Utilisation d'un nouvel agent naturel dans des compositions cosmetiques
DK1753360T3 (da) Rör- og universalkobling til at tilföre dentale eller kirurgiske instrumenter
EA201000559A1 (ru) Композиции и способы применения антител к склеростину
DK2303330T4 (da) Farmaceutiske sammensætninger til behandling af parkinsons sygdom
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
IL204741A (en) Ceramide History for the Treatment of Multiple Cyst Diseases and Pharmaceuticals Containing These History
FR2906716B1 (fr) Utilisation d'une composition cosmetique pour le soin des peaux grasses.
FR2921795B1 (fr) Utilisation d'une souche de bifidobacterium,pour la preparation d'une composition destinee a la prevention et/ou au traitement de manifestations de type allergique
FR2902325B1 (fr) Utilisation de 3h-1,2-dithiole-3-thione, d'anethole dithiomlethione, de sulforaphe, de phenethyl isothiocyanate, de 6-methyle-sulphinyl)hexyl isothiocyanate et d'allyl isothiocyanate pour le traitement de la canitie
BRPI0717671A2 (pt) "irrigador dental"
DE102009018133A8 (de) Pharmazeutische Zusammensetzung zur Behandlung von dermatologischen Autoimmunerkrankungen
FR2918282B1 (fr) Medicament pour le traitement de la maladie de parkinson
FR2906468B1 (fr) Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques
MA33813B1 (fr) Utilisation d'une source de l3 et/ou de l5 comme vaccin ou comme diagnostic pour une maladie parasitaire
ATE474574T1 (de) Imidazoazephinonverbindungen
FR2963237B1 (fr) Nouvelle composition pharmaceutique utile pour prevenir ou traiter l'hypotension arterielle peroperatoire chez l'etre humain
ATE422881T1 (de) Pharmazeutische zusammensetzungen auf basis von nk2-antagonisten für den pädiatrischen gebrauch
ATE481469T1 (de) Gewebepflegezusammensetzungen
FR2911507B1 (fr) Utilisation de lignanes et/ou pour l'obtention d'une composition pharmaceutique, cosmetique, dermatologique et/ou neutraceutique
EA200970376A1 (ru) Peg-илированный паратиреоидный гормон в качестве модулятора рецептора паратиреоидного гормона и его применение
FR2919999B1 (fr) Compositions d'acide hyaluronique
FR2906469B1 (fr) Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques chez l'homme
FR2901703B1 (fr) Utilisation de zatosetron pour le traitement de la rosacee, et compositions pharmaceutiques

Legal Events

Date Code Title Description
CD Change of name or company name

Owner name: APTISSEN SA, CH

Effective date: 20141217

TP Transmission of property

Owner name: APTISSEN SA, CH

Effective date: 20141217

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17